Company intelligence / Profile preview

Clear Creek Bio

Boston, Massachusetts, United Statesclearcreekbio.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

Clear Creek Bio develops oral small molecule therapeutics targeting viral diseases such as COVID‑19 and certain cancers. Their pipeline includes SARS-CoV‑2 PLpro inhibitors in discovery for COVID‑19, brequinar sodium previously investigated for neoplasms but now discontinued, and CC‑414 pending for acute myeloid leukemia. The company leverages research into new pathways important for viral replication and focuses on both host-targeting and direct antiviral approaches. No late-stage clinical results are reported as of the latest available information.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

brequinar sodium

Discontinued

Beyond the preview

Go deeper on Clear Creek Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clear Creek Bio.

Explore the full profile